Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Peter P. Sayeski"'
Autor:
Eun-Ju Lee, Daniel J. Dykas, Andrew D. Leavitt, Rodney M. Camire, Eduard Ebberink, Pablo García de Frutos, Kavitha Gnanasambandan, Sean X. Gu, James A. Huntington, Steven R. Lentz, Koen Mertens, Christopher R. Parish, Alireza R. Rezaie, Peter P. Sayeski, Caroline Cromwell, Noffar Bar, Stephanie Halene, Natalia Neparidze, Terri L. Parker, Adrienne J. Burns, Anne Dumont, Xiaopan Yao, Cassius Iyad Ochoa Chaar, Jean M. Connors, Allen E. Bale, Alfred Ian Lee
Publikováno v:
Blood Advances, Vol 1, Iss 16, Pp 1224-1237 (2017)
Abstract: Genetics play a significant role in venous thromboembolism (VTE), yet current clinical laboratory-based testing identifies a known heritable thrombophilia (factor V Leiden, prothrombin gene mutation G20210A, or a deficiency of protein C, pr
Externí odkaz:
https://doaj.org/article/c274b1de27734d959984c4c6623722ac
Autor:
Annet Kirabo, Sung O. Park, Anurima Majumder, Meghanath Gali, Mary K. Reinhard, Heather L. Wamsley, Zhizhuang Joe Zhao, Christopher R. Cogle, Kirpal S. Bisht, György M. Keserű, Peter P. Sayeski
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 11, Pp 1058-1068 (2011)
We recently developed a Janus kinase 2 (Jak2) small-molecule inhibitor called G6 and found that it inhibits Jak2-V617F– mediated pathologic cell growth in vitro, ex vivo, and in vivo. However, its ability to inhibit Jak2-V617F–mediated myeloproli
Externí odkaz:
https://doaj.org/article/70c68f511e8d44e5ab68dbc16ad18285
Autor:
Peter P. Sayeski, Annet Kirabo
Publikováno v:
Pharmaceuticals, Vol 3, Iss 11, Pp 3478-3493 (2010)
Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiote
Externí odkaz:
https://doaj.org/article/55745b60d0ab46a2804e0a70eb39c549
Autor:
Jermaine G. Johnston, Amanda K. Welch, Brian D. Cain, Peter P. Sayeski, Michelle L. Gumz, Charles S. Wingo
Publikováno v:
Comprehensive Physiology. :4409-4491
Autor:
Peter P. Sayeski, Raul C. Braylan, Robert W. Allan, David A. Ostrov, Andrew Magis, Jacqueline Sayyah
Supplementary Fig. from Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e03ad11b15cf241e032fc834176e07
https://doi.org/10.1158/1535-7163.22482332.v1
https://doi.org/10.1158/1535-7163.22482332.v1
Autor:
Peter P. Sayeski, Raul C. Braylan, Robert W. Allan, David A. Ostrov, Andrew Magis, Jacqueline Sayyah
Jak2 tyrosine kinase is essential for animal development and hyperkinetic Jak2 function has been linked to a host of human diseases. Control of this pathway using Jak2-specific inhibitors would therefore potentially serve as a useful research tool an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005dfae2218f77885d93d27466aea579
https://doi.org/10.1158/1535-7163.c.6530897.v1
https://doi.org/10.1158/1535-7163.c.6530897.v1
Autor:
Sung O Park, Heather L Wamsley, Kyungmi Bae, Zhongbo Hu, Xiaomiao Li, Se-woon Choe, William B Slayton, S Paul Oh, Kay-Uwe Wagner, Peter P Sayeski
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e59675 (2013)
Germline deletion of Jak2 in mice results in embryonic lethality at E12.5 due to impaired hematopoiesis. However, the role that Jak2 might play in late gestation and postnatal life is unknown. To understand this, we utilized a conditional knockout ap
Externí odkaz:
https://doaj.org/article/107094f9362e4f75bcb3a3f489558848
Autor:
Rebekah Baskin, György M. Keserű, Dávid Bajusz, Róbert Gábor Kiss, Katalin Monostory, Peter P. Sayeski, Katalin Tóth
Publikováno v:
Archiv der Pharmazie. 349:925-933
Janus kinases (JAKs) and their gain-of-function mutants have been implicated in a range of oncological, inflammatory, and autoimmune conditions, which has sparked great research interest in the discovery and development of small-molecule JAK inhibito
Autor:
Neeraj Kumar Singh, Ansu Kumar, Taher Abbasi, Peter P. Sayeski, Shireen Vali, Susumu Kobayashi
Publikováno v:
Oncotarget
Previous studies have shown that the bone marrow micro-environment supports the myeloproliferative neoplasms (MPN) phenotype including via the production of cytokines that can induce resistance to frontline MPN therapies. However, the mechanisms by w
Autor:
Kay Uwe Wagner, Peter P. Sayeski, Jonel Trebicka, Sabine Klein, Frank Erhard Uschner, Christian P. Strassburg, Kanishka Hittatiya, Jennifer Lehmann, Robert Schierwagen, Irela Schierwagen, Steffen Manekeller, Dominik Wolf, Wim Laleman, Johanna Rick, Tilman Sauerbruch, Len Verbeke
Publikováno v:
Gut. 66:145-155
Objective Angiotensin II (AngII) activates via angiotensin-II-type-I receptor (AT1R) Janus-kinase-2 (JAK2)/Arhgef1 pathway and subsequently RHOA/Rho-kinase (ROCK), which induces experimental and probably human liver fibrosis. This study investigated